Product Surveillance, Postmarketing
This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in the URMC Research Network by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publication.
Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Alexander GC, O'Connor AB, Stafford RS. Enhancing prescription drug innovation and adoption. Ann Intern Med. 2011 Jun 21; 154(12):833-7, W-301.
-
The role of the U.S. Food and Drug Administration in device evaluation and monitoring. Gastrointest Endosc. 2010 Jul; 72(1):5-10.
-
Berg MJ. What's the problem with generic antiepileptic drugs?: a call to action. Neurology. 2007 Apr 17; 68(16):1245-6.
-
Chambers CD, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK, Polifka JE, Robinson LK, Stepanuk K, Lyons Jones K. Postmarketing surveillance for human teratogenicity: a model approach. Teratology. 2001 Nov; 64(5):252-61.
-
Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000 Aug; 47(2):219-33.
-
Daum RS, Marcuse EK, Giebink GS, Hall CB, Lepow ML, McCracken GH, Peter G, Phillips CF, Wright HT, Plotkin SA. Haemophilus influenzae type b vaccines: lessons from the past. Pediatrics. 1988 Jun; 81(6):893-7.
